[go: up one dir, main page]

MX2017007232A - Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes. - Google Patents

Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes.

Info

Publication number
MX2017007232A
MX2017007232A MX2017007232A MX2017007232A MX2017007232A MX 2017007232 A MX2017007232 A MX 2017007232A MX 2017007232 A MX2017007232 A MX 2017007232A MX 2017007232 A MX2017007232 A MX 2017007232A MX 2017007232 A MX2017007232 A MX 2017007232A
Authority
MX
Mexico
Prior art keywords
biologics
antigens
proteins
mobility shift
present
Prior art date
Application number
MX2017007232A
Other languages
English (en)
Inventor
Singh Sharat
Chi-Kwan Ling Nicholas
Westin Stefan
Jain Anjali
SALBATO Jared
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2017007232A publication Critical patent/MX2017007232A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5434—IL-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona un ensayo de desplazamiento por movilidad homogéneo indirecto sensible y específico que usa cromatografía de exclusión de tamaño para medir productos biológicos tales como vedolizumab y ustekinumab en una muestra de paciente. Los ensayos de la presente invención son particularmente adecuados para detectar la presencia o el nivel de productos biológicos que se dirigen a antígenos complejos o grandes incluyendo proteínas de superficie celular, proteínas de transmembrana, proteínas fuertemente glicosiladas y proteínas multiméricas, así como antígenos que no pueden ser purificados, antígenos impuros, y antígenos parcialmente o sustancialmente purificados. La presente invención también proporciona heterodímeros de integrina a4ß7 solubles y aislados, y monómeros de IL-12p40 solubles y aislados que son adecuados para su uso en los ensayos indirectos descritos en la presente.
MX2017007232A 2014-12-05 2015-12-04 Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes. MX2017007232A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462088465P 2014-12-05 2014-12-05
US201562113317P 2015-02-06 2015-02-06
US201562158791P 2015-05-08 2015-05-08
PCT/IB2015/059381 WO2016088104A2 (en) 2014-12-05 2015-12-04 Indirect homogeneous mobility shift assays for the detection of biologics in patient samples

Publications (1)

Publication Number Publication Date
MX2017007232A true MX2017007232A (es) 2017-10-16

Family

ID=55025290

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007232A MX2017007232A (es) 2014-12-05 2015-12-04 Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes.

Country Status (15)

Country Link
US (3) US10422807B2 (es)
EP (2) EP3227683B1 (es)
JP (1) JP2018500553A (es)
KR (1) KR20170091717A (es)
CN (1) CN107250798A (es)
AU (1) AU2015356613A1 (es)
BR (1) BR112017011545A2 (es)
CA (1) CA2969609C (es)
ES (1) ES2735085T3 (es)
HK (1) HK1244880B (es)
IL (1) IL252396A0 (es)
MX (1) MX2017007232A (es)
RU (1) RU2017122720A (es)
SG (1) SG11201704200SA (es)
WO (1) WO2016088104A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101881714B1 (ko) 2009-10-26 2018-07-24 네스텍 소시에테아노님 항-ｔｎｆ 약물 및 자가항체의 검출을 위한 검정법
WO2013006810A1 (en) 2011-07-06 2013-01-10 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
MX2017007232A (es) 2014-12-05 2017-10-16 Nestec Sa Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes.
WO2021220251A1 (en) 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein
CN114624343B (zh) * 2020-12-10 2023-01-24 中国科学院大连化学物理研究所 一种用于血清中45种炎症及免疫代谢物相对定量的方法
CA3234491A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
CA3234496A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3107755A1 (de) 1981-02-28 1982-09-16 Degussa Ag, 6000 Frankfurt Katalysatoren fuer die herstellung von 3-cyanpyridin
US5700466A (en) 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US4459359A (en) 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4857456A (en) 1985-04-30 1989-08-15 The Regents Of The University Of California Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders
FR2590674B1 (fr) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
EP0440044A1 (en) 1990-01-31 1991-08-07 Abbott Laboratories Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing
US5094740A (en) 1990-02-16 1992-03-10 Glycomed, Inc. Two-dimensional electrophoretic separation of carbohydrates
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
JPH04303867A (ja) 1991-03-30 1992-10-27 Toshiba Corp 画像形成装置
US5582998A (en) 1991-06-19 1996-12-10 Boehringer Ingelheim International Gmbh Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor
JPH0566222A (ja) 1991-09-09 1993-03-19 Tosoh Corp 物質の分析方法
CA2146559A1 (en) * 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
JPH07110331A (ja) 1993-09-07 1995-04-25 Wako Pure Chem Ind Ltd ヒト補体価測定方法及びヒト補体価測定用試薬組成物
EP0642021B1 (en) 1993-09-07 2000-11-02 Wako Pure Chemical Industries Ltd Process for measuring complement activity and reagent used therefor
JPH07140144A (ja) 1993-11-19 1995-06-02 S R L:Kk アレルゲン特異的ＩｇＥ抗体の測定方法および抗原抗体複合体の測定方法
ES2196098T3 (es) 1994-12-28 2003-12-16 Univ Kentucky Res Found Secuencias anticuerpos anti-idiotipo 3h1 monoclonales relacionadas con el antigeno carcinoembrionico humano.
US6903183B1 (en) 1996-06-07 2005-06-07 Texas Tech University Health Services Center Compositions and methods for regulation of steroidogenesis
JP3718435B2 (ja) 1996-08-12 2005-11-24 積水化学工業株式会社 細胞機能測定用容器及び細胞機能測定方法
US6458548B2 (en) 1996-08-12 2002-10-01 Sekisui Kagaku Kogyo Kabushiki Kaisha Containers and kits for the determination of cell functions, and method for the determination thereof
US6391622B1 (en) 1997-04-04 2002-05-21 Caliper Technologies Corp. Closed-loop biochemical analyzers
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
DE19858777B4 (de) 1998-12-18 2006-07-27 Delta Biotechnology Ltd. Verfahren zur teilweisen oder vollständigen Trennung von glykosilierten und nicht-glykosilierten Proteinen
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
CA2394536A1 (en) 1999-12-16 2001-06-21 Amgen Inc. Tnfr/opg-like molecules and uses thereof
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
CA2440219A1 (en) * 2001-02-21 2002-10-17 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
EP1637601A3 (en) * 2001-02-21 2006-03-29 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
EP1370867B1 (en) 2001-03-02 2010-08-04 Activx Biosciences, Inc. Protein profiling platform
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2002356180A1 (en) * 2001-08-06 2003-03-10 The Regents Of The University Of California Methods for inhibiting angiogenesis
US20030040027A1 (en) 2001-08-16 2003-02-27 Gerd Ritter Method for determining protein component in a biological sample
MXPA04004417A (es) 2001-11-12 2004-08-11 Merck Patent Gmbh Anticuerpo anti-tnf alfa modificado.
US20060110407A1 (en) 2001-12-05 2006-05-25 Shelley Stopera Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
GB0208817D0 (en) 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
MXPA05001268A (es) 2002-08-01 2005-10-06 Wyeth Corp Metodos y reactivos relacionados con la inflamacion y apoptosis.
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
WO2005094200A2 (en) 2003-06-20 2005-10-13 University Of Florida Biomarkers for differentiating between type 2 and type 2 diabetes
RU2006101216A (ru) 2003-08-01 2007-07-20 Амген Инк. (US) Кристаллические полипептиды 2 фактора некроза опухолей
WO2005019271A1 (en) 2003-08-14 2005-03-03 Wyeth Anti-lewis y anti-idiotypic antibodies and uses thereof
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
WO2005072340A2 (en) * 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
US20090275496A1 (en) 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
EP1769244A4 (en) 2004-06-30 2008-05-14 Dow Kenneth Centocor Inc DETECTION OR MEASUREMENT OF ANTIGEN PROTEIN ANTIBODIES IN BIOLOGICAL TISSUE OR SAMPLES
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
KR20080046135A (ko) 2005-05-20 2008-05-26 제넨테크, 인크. 자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리
JP2009501913A (ja) 2005-07-21 2009-01-22 ゲンマブ エー／エス Ｆｃ受容体と結合する抗体原薬に関する効力アッセイ
US20090162374A1 (en) 2005-09-14 2009-06-25 Geraghty Daniel E Specific removal of activated immune cells
US7542502B2 (en) 2005-09-27 2009-06-02 Cymer, Inc. Thermal-expansion tolerant, preionizer electrode for a gas discharge laser
EP1948214A4 (en) 2005-11-08 2009-12-30 Medarex Inc ANTI-TNF-ALPHA TREATMENT FOR TREATING ENTEROCOLITIS ASSOCIATED WITH IMMUNOSTIMULATORY THERAPEUTIC ANTIBODY TREATMENT
JP2007147367A (ja) 2005-11-25 2007-06-14 Sekisui Chem Co Ltd サイトカイン産生能の測定方法
DE102005057920A1 (de) 2005-12-02 2007-06-28 Strohner, Pavel, Dr. Immunoassay zur simultanen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers in Proben
US20100130367A1 (en) 2006-07-11 2010-05-27 Drexel University Methods of Quantitatively Assessing Inflammation with Biosensing Nanoparticles
EP2639319B1 (en) * 2006-09-11 2015-07-08 Celera Corporation Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof
US20080286774A1 (en) * 2007-05-16 2008-11-20 The Regents Of The University Of California Real-time individualized therapy evaluation
CA2693013A1 (en) 2007-07-13 2009-01-22 Prometheus Laboratories Inc. Drug selection for lung cancer therapy using antibody-based arrays
US20090035216A1 (en) 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
CA2712021A1 (en) 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Methods and kits for detecting antibodies against therapeutic antibodies
CN102016552A (zh) 2008-03-05 2011-04-13 神谷来克斯公司 用于分子的高灵敏性检测的方法和组合物
US8877893B2 (en) * 2008-12-29 2014-11-04 Children's Medical Center Corporation Stabilized low affinity conformation of integrins for drug discovery
KR101881714B1 (ko) 2009-10-26 2018-07-24 네스텍 소시에테아노님 항-ｔｎｆ 약물 및 자가항체의 검출을 위한 검정법
EP2547359B1 (en) * 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibitors of beta integrin-g protein alpha subunit binding interactions
JP5066222B2 (ja) 2010-05-31 2012-11-07 三菱電機株式会社 ネットワーク解析支援装置、ネットワーク解析支援方法及びプログラム
WO2012032181A2 (en) 2010-09-10 2012-03-15 Allozyne, Inc Novel antibody derivatives
MX344053B (es) 2010-10-18 2016-12-02 Nestec Sa Metodos para determinar isotipos de anticuerpos anti-farmacos.
KR20140008397A (ko) 2011-02-17 2014-01-21 네스텍 소시에테아노님 항-ＴＮＦα 약물에 대한 자가항체 검출을 위한 검정법
TWI723339B (zh) 2011-05-02 2021-04-01 美商千禧製藥公司 抗-α4β7抗體之調配物
JP2014517279A (ja) 2011-05-10 2014-07-17 ネステク ソシエテ アノニム 個別治療管理のための疾患活動性プロファイリングの方法
MX363606B (es) * 2011-06-22 2019-03-28 Apellis Pharmaceuticals Inc Uso de inhibidores del complemento en trastornos crónicos.
CN103619874A (zh) * 2011-06-30 2014-03-05 株式会社免疫生物研究所 可溶性整联蛋白α4突变体
WO2013006810A1 (en) * 2011-07-06 2013-01-10 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
US20130266963A1 (en) 2011-07-06 2013-10-10 Nestec S.A. Assay for detecting neutralizing autoantibodies to biologic therapy
WO2013126595A1 (en) * 2012-02-21 2013-08-29 Massachusetts Eye And Ear Infirmary Methods for treating corneal and conjunctival inflammation and inflammatory disorders
US20130295685A1 (en) 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
US20140051184A1 (en) * 2012-08-15 2014-02-20 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto
BR112015012482A2 (pt) 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
WO2015073580A1 (en) 2013-11-13 2015-05-21 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
MX2017007232A (es) 2014-12-05 2017-10-16 Nestec Sa Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes.
KR102423893B1 (ko) 2015-03-31 2022-07-21 삼성디스플레이 주식회사 플렉서블 표시 장치
CN118873822A (zh) 2016-12-14 2024-11-01 比奥拉治疗股份有限公司 使用tnf抑制剂治疗胃肠道疾病

Also Published As

Publication number Publication date
US20170328923A1 (en) 2017-11-16
BR112017011545A2 (pt) 2018-03-13
US20240183867A1 (en) 2024-06-06
JP2018500553A (ja) 2018-01-11
CA2969609C (en) 2023-02-28
EP3227683A2 (en) 2017-10-11
AU2015356613A1 (en) 2017-06-15
EP3227683B1 (en) 2019-04-24
IL252396A0 (en) 2017-07-31
ES2735085T3 (es) 2019-12-16
CA2969609A1 (en) 2016-06-09
US20200088749A1 (en) 2020-03-19
HK1244880B (zh) 2020-06-05
US10422807B2 (en) 2019-09-24
US11846642B2 (en) 2023-12-19
CN107250798A (zh) 2017-10-13
SG11201704200SA (en) 2017-06-29
WO2016088104A2 (en) 2016-06-09
WO2016088104A3 (en) 2016-08-18
RU2017122720A (ru) 2019-01-10
EP3536705A1 (en) 2019-09-11
KR20170091717A (ko) 2017-08-09

Similar Documents

Publication Publication Date Title
MX2017007232A (es) Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes.
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
AU2018200278B2 (en) Antibodies to aripiprazole and use thereof
MX2017015011A (es) Ensayo a base de celulas para detectar homodimeros anti-cd3.
MX366275B (es) Metodos para detectar y medir la agregacion.
CO2017002710A2 (es) Sistemas y métodos para la integración de la recolección de microfluido lagrimal y el análisis por flujo lateral de analitos de interés
MX2020001227A (es) Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
NZ599456A (en) Assays for the detection of anti-tnf drugs and autoantibodies
EP3933406A3 (en) Antibodies to risperidone and use thereof
MX2017003269A (es) Detección de las proteínas mal plegadas.
CL2019002264A1 (es) Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet.
IN2015DN01876A (es)
BR112017009151A2 (pt) ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
MX2016001573A (es) Ensayos para timp2 con mejor rendimiento en muestras biológicas.
WO2016209773A9 (en) Improved assays and methods for allergen detection
SG10201807867XA (en) Simultaneous detection of target protein and target nucleic acids in a single cell
MX2015001961A (es) Metodos y sistemas para ensayos.
WO2013165972A3 (en) Anti-hepatitis b virus antibodies and use thereof
IT201600073964A1 (it) Nanointerruttore basato su nucleotidi e metodi per la rilevazione di anticorpi e altri analiti
EP3721229A4 (en) LATERAL FLOW ASSAY AND METHOD OF DETECTING HIGH CONCENTRATION ANALYTES
EA201500377A1 (ru) Способ обнаружения анализируемого вещества и определение его концентрации с использованием намагничиваемых гранул
MX2016010499A (es) Sistemas y métodos para identificar subtipos del receptor de progesterona.
WO2014151290A3 (en) Assay for predictive biomarkers
WO2015134928A3 (en) Point of care assays to detect the status of tuberculosis infection
MX2015015023A (es) Metodo para la determinacion de cobre libre.